Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Results of Allogeneic Transplantation As First Line Rescue Therapy in Patients with Multiple Myeloma Relapsing to a Prior Autograft: Role of Conditioning Regimen

Jose A. Perez-Simon, MD, PhD, Francisco J Marquez-Malaver, RN, Cora Knol, Simona Iacobelli, Didier Blaise, MD PhD, Noel-Jean Milpied, MD PhD, Ellen Meijer, MDPhD, Peter Dreger, MD, Yener Koc, MD, Eefke Petersen, MD PhD, Mauricette Michallet, MD PhD, Laurent Garderet, Nicolaus Kroeger, MD

Blood (2015) 126 (23): 4373.

https://doi.org/10.1182/blood.V126.23.4373.4373

Published: 2015

Journal Articles

Autologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission: Better Outcome Following Busulfan and Melphalan Compared to Busulfan and Cyclophosphamide : A Retrospective Study from the Acute Leukemia Working Party of the EBMT

Norbert Claude Gorin, Pr, MD PhD, Myriam Labopin, MD, Tomasz Czerw, MD, Kurt Leibundgut, MD, Didier Blaise, MD PhD, Pierre Yves Dumas, MD PhD, Damir Nemet, MD PhD, William Arcese, MD, Roberto Foa, MD, Wu Depei, MD, Anne Huynh, MD, Tsila Zuckerman, MD, Ellen Meijer, MDPhD, Seckin Cagirgan, PhD MD, Jan Cornelissen, MD PhD, Mohamad Mohty, MD PhD, Arnon Nagler, MD MSc

Blood (2015) 126 (23): 926.

https://doi.org/10.1182/blood.V126.23.926.926

Published: 2015

Journal Articles

Treatment of Chronic Graft Versus Host Disease with a Combination of B-Cell Depletion and Tyrosine Kinase Inhibition

Lotte van der Wagen, MD, Liane CJ te Boome, MD, Inger Nijhof, Marieke Schoordijk, Denise Buter, Ellen Meijer, MDPhD, Jurgen Kuball, MDPhD

Blood (2015) 126 (23): 1939.

https://doi.org/10.1182/blood.V126.23.1939.1939

Published: 2015

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Evolution and Outcomes over More Than Two Decades within EBMT Centers

Blood (2014) 124 (21): 2554.

https://doi.org/10.1182/blood.V124.21.2554.2554

Published: 2014

Journal Articles

Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma

Annemiek Broijl, MDPhD, Marie José Kersten, MD PhD, Wendim Ghidey Alemayehu, PhD, Mark-David Levin, MDPhD, Okke de Weerdt, MD, Edo Vellenga, MDPhD, Ellen Meijer, MDPhD, Shulamiet Wittebol, MDPhD, Rosita Ghiraw-Visser, Marian Stevens-Kroef, PhD, Berna Beverloo, PhD, Gerard M.J. Bos, MDPhD, Pierre W. Wijermans, MDPhD, Henk Lokhorst, MDPhD, Pieter Sonneveld, MDPhD

Blood (2014) 124 (21): 4735.

https://doi.org/10.1182/blood.V124.21.4735.4735

Published: 2014

Journal Articles

Allogeneic HCT with Reduced Intensity Conditioning Versus Autologous HCT for >55 Years Old Patients with Acute Lymphoblastic Leukemia in First Complete Remission: An Analysis from Acute Leukemia Working Party of the EBMT

Sebastian Giebel, Myriam Labopin, MD, Norbert Claude Gorin, MD, Noel Milpied, MD PhD, Eefke Petersen, MDPhD, Michael N Potter, MD PhD, Jan J. Cornelissen, MD PhD, Denis Caillot, MD, Dietger Niederwieser, MD, Rovira Montserrat, Pavel Jindra, MD PhD, Ellen Meijer, MDPhD, Johan Maertens, MD, Alessandro Rambaldi, MD, Arnon Nagler, MD, Mohamad Mohty, MD PhD

Blood (2014) 124 (21): 3974.

https://doi.org/10.1182/blood.V124.21.3974.3974

Published: 2014

NARROW

Results of Allogeneic Transplantation As First Line Rescue Therapy in Patients with Multiple Myeloma Relapsing to a Prior Autograft: Role of Conditioning Regimen

Autologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission: Better Outcome Following Busulfan and Melphalan Compared to Busulfan and Cyclophosphamide : A Retrospective Study from the Acute Leukemia Working Party of the EBMT

Treatment of Chronic Graft Versus Host Disease with a Combination of B-Cell Depletion and Tyrosine Kinase Inhibition

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Evolution and Outcomes over More Than Two Decades within EBMT Centers

Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma

Allogeneic HCT with Reduced Intensity Conditioning Versus Autologous HCT for >55 Years Old Patients with Acute Lymphoblastic Leukemia in First Complete Remission: An Analysis from Acute Leukemia Working Party of the EBMT

Email alerts

ASH Publications

American Society of Hematology

Results of Allogeneic Transplantation As First Line Rescue Therapy in Patients with Multiple Myeloma Relapsing to a Prior Autograft: Role of Conditioning Regimen

Autologous Stem Cell Transplantation for Adult Acute Myelocytic Leukemia in First Remission: Better Outcome Following Busulfan and Melphalan Compared to Busulfan and Cyclophosphamide : A Retrospective Study from the Acute Leukemia Working Party of the EBMT

Treatment of Chronic Graft Versus Host Disease with a Combination of B-Cell Depletion and Tyrosine Kinase Inhibition

Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Evolution and Outcomes over More Than Two Decades within EBMT Centers

Phase I/II Trial of Weekly Escalated Dose Bortezomib Combined with Lenalidomide and Dexamethasone in Patients in First Relapse or Primary Refractory Disease after First Line Therapy for Multiple Myeloma

Allogeneic HCT with Reduced Intensity Conditioning Versus Autologous HCT for >55 Years Old Patients with Acute Lymphoblastic Leukemia in First Complete Remission: An Analysis from Acute Leukemia Working Party of the EBMT

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only